SPRO

Spero Therapeutics (SPRO)

About Spero Therapeutics (SPRO)

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on identifying, developing, and commercializing treatments involving bacterial infections, including multi-drug resistant bacterial infections, and rare diseases Its pipeline product candidates include Tebipenem HBr, SPR720, and SPR206. The company was founded by Ankit A. Mahadevia and Laurence Rahme in April 2013 and is headquartered in Cambridge, MA.

Details

Daily high

$2.36

Daily low

$2.16

Price at open

$2.28

52 Week High

$3.22

52 Week Low

$1.80

Market cap

132.0M

Dividend yield

0.00%

Volume

123,628

Avg. volume

1.8M

P/E ratio

9.36

Spero Therapeutics News